Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata” or the "Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other ...
Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., ...
Throughout her journey, Brett found ways to reclaim control — through cooking cancer-fighting meals, walking with her husband, detox baths, meditation, and Reiki therapy. “You lose so much when you’re ...
Just a year after being diagnosed with breast cancer, and following three surgeries, 15 hours of radiation treatments and ...
About 60% women in Europe enrolled in a national breast cancer screening programme who have a screening mammogram can feel reasonably confident that radiologists will be able to diagnose early-stage ...
Longer-term trial results show Voranigo may help control grade 2 IDH-mutated glioma after surgery for those who can delay ...
Stage 2 prostate cancer is considered localized, meaning the cancer is still confined entirely within the prostate gland and has not spread to nearby lymph nodes (node 0 or N0) or distant parts of the ...
In HR+/HER- early breast cancer, the DFS benefits of adjuvant ribociclib plus NSAI treatment compared to NSAI alone persisted even a year after treatment completion.
Researchers present an overview of treatment and management strategies for patients with HR+/HER2+ breast cancer, including common adverse effects.
Waiting and seeing is not often the strategy employed when it comes to treating breast cancer, but a new clinical trial by the University of California, San Francisco, researchers are doing just that.
Almost immediately after Theresa Greco was diagnosed with breast cancer in March, doctors asked her whether she wanted to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback